Home / PDA Letters (Cards)

PDA Letters (Cards)

Blockchain: Will it Transform the Pharmaceutical Supply Chain?

Mark Crawford

A Not-So-Sweet Smell: Part II

Anthony Newcombe, PhD, and Siegfried Schmitt, PhD, PAREXEL

Are You Ready for the eCTD Mandate?

Mckenzie Orchowski, Biologics Consulting

Quality/Compliance Management for Virtual Companies

David Chesney, DL Chesney Consulting

Five Critical Endotoxin Testing Concerns

Jennifer Farrington, PhD, Associates of Cape Cod, and Friedrich von Wintzingerode, PhD, Roche Diagnostics GmbH

Opportunities to Build and Grow Your Network

Rebecca Stauffer, PDA

Visual Inspection Remains Critical

John Shabushnig, PhD, Insight Pharma Consulting, and Markus Lankers, PhD

How to Best Tackle Biosimilar Challenges

Stephan Krause, PhD, AstraZeneca Biologics, and Jens Schletter, PhD, Novartis

3 Questions for Biogen’s Amy Wilson

Rebecca Stauffer, PDA

Pharma Must Work “Smarter” in New Era

Toni Manzano, bigfinite

Chapter Grows Professional Opportunities Across Industry

Elizabeth Hunt, Pharmalex, Ireland Chapter Event and Media Administrator

Prospects for Post-Approval Change Management

Naheed Sayeed-Desta, Apotex, Ajay Babu Pazhayattil, and Ivy Louis, Vienni Training and Consulting LLP

Eyeing the Future of Biomanufacturing

Victoria Hayes, ICQ

A Not-So-Sweet Smell: Part I

Siegfried Schmitt, PhD, and Anthony Newcombe, PhD, PAREXEL Consulting

Can ICH Q12 Unlock Manufacturing Innovation?

Ursula Busse, PhD, Novartis, and Melissa Seymour, Biogen

Growing Acceptance of Real-Time Monitoring

Frank Panofen, Particle Measuring Systems

Seeing the Light

Anders Vinther, PhD

Getting Biosimilars Right the First Time

Barbara Rellahan, Amgen

Knowledge Grows for mAb Development

Martijn van der Plas, PhD, Medicines Evaluation Board, and Michael De Felippis, PhD, Eli Lilly

A Wealth of New Tech Possibilities

Scott Bozzone, PhD, Pharm Lifecycle Validation LLC